Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Biophytis ( (BPTSY) ).
On July 11, 2025, Biophytis SA announced its 2024 financial results and strategic outlook for 2025. The company reported significant progress in its clinical programs, including the launch of the OBA program for obesity and major advancements in the SARA program for sarcopenia. Biophytis plans to initiate a Phase 2 study in obesity and a Phase 3 study in sarcopenia, while continuing its partnership strategy to fund these initiatives. The company also aims to strengthen its drug discovery platform by integrating disruptive technologies. Despite a reduction in operating losses and strengthened equity, Biophytis faces material uncertainty regarding its ability to continue as a going concern due to insufficient cash reserves to fund operations beyond the third quarter of 2025.
The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company that focuses on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is being developed for muscular diseases such as sarcopenia, with a Phase 3 trial ready to start, and metabolic disorders like obesity, with a Phase 2 trial ready to start. The company is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts, USA, and Brazil.
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.38M
See more data about BPTSY stock on TipRanks’ Stock Analysis page.